Novartis
NEWS
A Novartis leukemia drug continues to be the subject of a handful of lawsuits filed by plaintiffs due to concerns over atherosclerosis-related conditions.
Following an agreement to sell its share of a consumer health business unit to GlaxoSmithKline for $13 billion new Novartis Chief Executive Officer Vasant Narasimhan has some excess cash to use to shape the company in the coming years.
Homology Medicines has raised $144 million in an initial public offering of stock.
As Novartis locks in on a $13 billion deal with GlaxoSmithKline (GSK), Novartis chief executive officer Vasant Narasimhan confirms that any decision about spinning off its Alcon eye care business won’t be made until the first half of 2019.
GlaxoSmithKline walked away from a potential deal to acquire Pfizer’s consumer health unit four days ago and instead opted to acquire the stake controlled by Novartis. The deal will give GSK 100 percent ownership of the business unit.
Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.
Novartis released full results from its Phase III EXPAND trial of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS), which it published in the journal The Lancet.
Companies that have a strong focus on developing drugs that target messenger RNA (mRNA) may be ahead of the curve when it comes to potentially tapping into a lucrative market space.
IDEAYA Biosciences has raised $94 million in Series B funding to drive multiple clinical studies in 2019.
JOBS
IN THE PRESS